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Coats’ disease first described in 1908,1 is an idiopathic, typically unilateral, retinal vasculopathy that manifests with retinal telangiectasia, exudation, and retinal
detachment.2–4 Coats’ disease shows a male predominance, occurs more often in
early childhood, and can lead to vision loss. Less commonly, this condition presents
in teenagers and young adults often with less aggressive features.4 Coats’ disease is a
major simulator of retinoblastoma, a life-threatening pediatric ocular malignancy.1–4
In a study of angiographic findings of patients with Coats’ disease, we noticed
that occlusion of the retinal microvasculature with peripheral nonperfusion and shunt
or microshunt formation between arterioles and venules in the retina was a prominent finding.5 This led to a speculation regarding serum factors that could lead to the
microocclusions, such as a hypercoagulability state. Realizing that such a state would
more likely lead to bilateral manifestations, we continued to explore serum features in
Coats’ disease. In 2012, we found a significantly high level of anti-cytomegalovirus
(CMV) immunoglobulin G (IgG) in 92% of Coats’ patients, higher serum proteins C
and S, anti-herpes simplex virus (HSV) IgG I/II, alpha-2 globulin, and homocysteinemia in patients with Coats’ disease.6 In the second step of the analysis, it was
planned to compare these factors in patients with Coats’ disease with a control group.
Herein, we evaluated serum hypercoagulable factors and viral and protozoan diseases
in patients with Coats’ disease versus normal controls.
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Purpose: The purpose of this study was to investigate the serum hypercoagulability state and
common viral and protozoan infections in Coats’ disease versus a normal control group.
Materials and methods: In this comparative case series, 22 consecutive patients with Coats’
disease and 19 non-Coats’ patients undergoing lensectomy for congenital, traumatic, or senile
cataract between January 2011 and June 2014 were included. Laboratory data for hypercoagulability states and common viral and protozoan infections were investigated.
Results: The mean age for the Coats’ group was 14.5 years (median 8 years, range: 2 months
to 59 years), and for the control group it was 30.6 years (median 17 years, range: 2–82 years).
In patients aged 10 years or younger, anticytomegalovirus immunoglobulin G (IgG) (P#0.01),
homocysteine (P=0.03), and serum beta globulin (P,0.001) were associated with Coats’ disease. In those older than 10 years, higher serum protein S (P=0.04), beta globulin (P=0.05),
and gamma globulin (P=0.04) were related to Coats’ diagnosis. After adjusting for sex and age
as confounding factors, only beta globulin was found to be associated with Coats’ disease in
logistic regression analysis (odds ratio: 1.8, 95% confidence interval: 1.0–3.1, P=0.02).
Conclusion: Serum beta globulin levels appear to be elevated in patients with Coats’ disease.
Keywords: anti-cytomegalovirus antibody, anti-herpes simplex antibody, Coats’ disease, blood
hypercoagulability state, retinal telangiectasia, serum electrophoresis
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Materials and methods
A prospective, single-center, comparative, consecutive crosssectional study was conducted for evaluating blood hypercoagulability state and infectious diseases, including CMV, herpes
simplex, Epstein-Barr virus (EBV), toxoplasma and toxocara
infections, in all patients with Coats’ disease from February
2011 to December 2013. The research adhered to the tenets
of the Declaration of Helsinki and the study was approved by
Tehran University of Medical Sciences Institutional Review
Board. Each patient or parents were carefully informed about
the purpose of the research, and oral consent for laboratory
examinations was obtained. Each patient or parents provided
their written informed consent for this study.
Coats’ disease was defined as unilateral or bilateral retinal
vasculopathy characterized by retinal telangiectasia, capillary
non-perfusion, multiple aneurysmal formation, exudation,
and exudative retinal detachment.1–9 Patients with Coats’
disease were grouped into those aged 10 years or less versus
those older than 10 years. Clinical factors were compared
to a control group, which consisted of patients with cataract
undergoing lensectomy for congenital, traumatic, or senile
cataract, with no evidence of retinal vascular disease.
Patients were evaluated with best-corrected visual acuity,
indirect ophthalmoscopy for fundus features and color fundus
photography, fluorescein angiography, and B-scan echography as needed. Fluorescein angiography was performed
using a scanning laser ophthalmoscope (HRA, Heidelberg,
Germany) or RetCam 120 (Clarity Medical Systems, Inc.,
Pleasanton, CA, USA).
The blood sample for serum studies was obtained from
patients immediately before the treatment of Coats’ disease.
Treatment options included cryotherapy, photocoagulation,
and intravitreal antivascular endothelial growth factor and/or
subtenon triamcinolone depending on the patient’s condition.
Serum studies included hemoglobinopathies by hemoglobin
electrophoresis; serum protein electrophoresis; coagulable
states by serum protein C, protein S level, antiphospholipid antibody, anticardiolipine antibody, antithrombin III,
homocysteine level, and lipid profile; and infectious states
by anti-HSV IgG, anti-CMV IgG, anti-EPV, anti-toxoplasma
and anti-toxocara serum antibodies were measured with a
enzyme-linked immunosorbent assay (ELISA) technique
according to the manufacturer’s protocol.

Statistical analysis
Statistical analyses were performed using Statistical Package
for Social Sciences (v 17.0; SPSS, Chicago, IL, USA). All
data are presented as mean ± standard deviation (SD) or
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median (range of data). A Mann–Whitney test was used for
quantitative or skewed distributed parameters. To assess
the relationship between the qualitative variable and Coats’
diagnosis, Fisher’s exact test was applied. Logistic regression
models were used to assess the relation of target exposure
with Coats’ diseases adjusting for possible confounding
factors. A P-value of less than 0.05 was considered to be
statistically significant.

Results
During the study period, there were 22 patients with Coats’
disease (Figure 1) and 19 control patients. Of those with
Coats’ disease, 13 were 10 years or younger and 9 were older.
(Table 1). The mean age for Coats’ patients was 14.5 years
(median 8 years, range: 2 month to 59 years), and for the
control group it was 30 years (median 17 years, range:
2–82 years) (Table 2).
For those 22 patients with Coats’ disease, the mean time
from the first notice of the disease by patients (or parents)
to diagnosis was 7.1±5.4 months in the younger age group
(#10 years old) and 7.8±9.9 months in the older age group
(.10 years old). There were three (13.6%) with bilateral
involvement. Using the Coats’ disease classification,4 the conditions of the eyes were classified as stage 1 (n=0), stage 2 (n=7),
stage 3 (n=12), stage 4 (n=3), and stage 5 (n=0). Total retinal
detachment was seen in six (28%) cases, whereas macular
detachment was seen only in three (14%) cases. In two (9%)
cases, there was no retinal detachment. The temporal and inferior regions were the most common sites for retinal detachment.
Using fluorescein angiography, avascular non-perfused areas
were found in 18 (82%) cases, located in the periphery region
in 10 (46%) and in the macular region in 2 (9%) (Table 1).
The first step of analysis was a comparison of the two
age groups of Coats’ disease (#10 years vs .10 years). This
revealed no significant difference in the lipid profile, serum
antithrombin III, anticardiolipine and antiphospholipid antibody serum antibody titer as well as polymerase chain reaction
test for toxoplasma, toxocara, or EBV in the two groups.
There was statistical difference (Mann–Whitney test-skewed
deviation) in the two groups with regard to hemoglobin
(P=0.02), serum anti-HSV IgG (P=0.05), anti-CMV IgG
(P=0.05), protein C (P=0.07), homocysteine (P,0.01),
serum alpha-2 globulin (P,0.01), and serum gamma globulin
(P=0.05). Due to the small sample size in each age group, the
logistic regression analysis was inconclusive.
The second step of analysis involved comparison of laboratory findings in Coats’ disease versus the normal control
group (Table 2). The serum levels in both Coats’ and control
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Figure 1 Clinical appearance of a patient with Coats’ disease. (A and B) The fundus image of a patient with Coats’ disease with exudative total retinal detachment. There
is central arteriolar mild dilation and tortuosity. Peripheral telangiectatic vessels along aneurysmal changes are visible. Many microvascular shunts nearly in 360° of periphery
and midperiphery of retina are evident. (C and D) Angiographic finding as telangiectatic vessels, microaneurysms, sacular aneurysms, shunt vessels and peripheral avascular
area in temporal and inferior retina.

patients were compared using the Mann–Whitney test. There
was no significant difference in the lipid profile, serum antithrombin III, anticardiolipine, and antiphospholipid antibody
serum antibody titer as well as polymerase chain reaction
for toxoplasma, toxocara, or EBV. However, in the control
group, the serum titer of anti-HSV IgG was higher and that
of anti-CMV IgG was lower. In Coats’ group, serum beta
globulin was significantly higher in both young (#10 years,
P,0.001) and old (.10 years, P=0.05) subgroups compared
to controls. Applying Bonferroni correction did not change
the results of serum beta globulin in the group less than 10
years old.
Logistic regression analysis for the main serologic findings in Coats’ patients (irrespective of age) and control group
was performed. After adjustment for age and sex, a significant association persisted for the presence of higher titer of
serum beta globulin in Coats’ disease compared to controls
(odds ratio [OR]: 1.8, 95% confidence interval [CI]: 1.0–3.1,
P=0.02) (Table 3). Anti-HSV showed a mild negative impact
(P=0.01, OR =−0.94) on the diagnosis of Coats’ disease.
After adjusting for age and sex, in those less than 10 years,

Clinical Ophthalmology 2017:11

the serum beta globulin was found to be significantly associated with the diagnosis of Coats’ disease (OR: 6.3, 95%
CI: 1.2–32.6, P=0.02). In patients greater than 10 years with
Coats’ disease, there was a non-significant association with
the diagnosis of Coats’ disease (OR: 1.3, 95% CI: 0.8–2.0,
P=0.24). For the older age, anti-HSV antibody was borderline
significant (OR: 0.98, 95% CI: 0.97–1.00, P=0.05). The small
sample size precluded more conclusive results in the logistic
regression analysis, adjusting for all other covariates.

Discussion
In this study, we could not find any association between
hypercoagulability state and Coats’ disease (compared to
controls). The only factor associated with Coats’ disease
was elevated serum beta globulin mainly in the younger age
group. We also recognized the negative impact of anti-HSV
antibody on Coats’ disease in the older age group.
Serum beta globulins are grossly measured by electrophoresis. Serum protein electrophoresis is a technique to
assess the two major fractions of protein in blood, including
albumin and globulins.10 Albumin is a transport protein that
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Features
Sex
Male
Female
Eye affected
Right
Left
Laterality
Unilateral
Bilateral
Telangiectatic vessels
Aneurysms
Exudation
Subretinal fluid
Tractional retinal detachment
Subretinal fibrosis
Retinal traction
Subretinal hemorrhage
Vitreous hemorrhage
Pre-retinal hemorrhage
Vasoproliferative tumor
Retinal cyst
Pigmentary changes
Cystic changes in vitreous
Fibroglial tissue
Subretinal band
Retinal fold
Vascular sheeting
(arterioles and/or venules)
Vascular occlusion
(large arterioles and/or venules)
Peripheral non-perfusion
(more temporal)
Shunt vessels
Retinal tear

Age #10 years
(13 cases) N (%)

Age .10 years
(9 cases) N (%)

Fisher’s exact test
P-value

8 (61.5)
5 (38.5)

6 (66.7)
3 (33.3)

1.00

8 (61.5)
5 (38.5)

5 (55.6)
4 (44.4)

0.23

10 (76.9)
3 (23.1)
10 (76.9)
9 (69.2)
9 (69.2)
10 (76.9)
6 (46.2)
5 (38.5)
2 (15.4)
3 (23.1)
0 (0)
3 (23.1)
2 (15.4)
5 (38.5)
6 (46.2)
0 (0)
4 (30.7)
3 (23.1)
2 (15.4)
8 (61.5)

9 (100)
0 (0)
4 (44.4)
4 (44.4)
9 (100)
5 (55.6)
3 (33.3)
1 (11.1)
2 (22.2)
1 (11.1)
0 (0)
0 (0)
2 (22.2)
2 (22.2)
2 (22.2)
1 (11.1)
1 (11.1)
1 (11.1)
1 (11.1)
2 (22.2)

0.23

3 (23.1)

0 (0)

0.49

6 (46.2)

1 (11.1)

0.68

1 (7.6)
2 (15.4)

0 (0)
0 (0)

0.68
0.50

0.51
0.37
0.13
0.52
0.50
1.00
0.70
1.00
1.00
0.53
0.52
1.00
0.48
0.09
0.41
0.53
0.10
0.25

Table 2 Coats’ disease based on the age category: comparison of serum values with normal controls
Features

Age #10 years median (range)

Age (Mo)
WBC (×103/dL)
Hb (g/dL)
PLT (103/dL)
Serum anti-HSV IgG ,20 (U/mL)
Serum anti-CMV IgG ,1 (U/mL)
Protein C (70–130 unit%)
Protein S
(male: 77–143,
female: 55–125 unit%)
Homocysteine
Serum albumin (g/dL)
Serum α1 globulin (2–6 g/dL)
Serum α2 globulin (8–13 g/dL)
Serum β globulin (12–19 g/dL)
Serum γ globulin (15–25 g/dL)

Age .10 years median (range)

Coats’ disease
group
(13 cases)

Control
group
(9 cases)

Mann–Whitney
(P-value)

Coats’ disease
group
(9 cases)

Control
group
(10 cases)

Mann–Whitney
(P-value)

48 (2–120)
8.8 (5–61)
13.3 (9.4–15)
372.5 (260–627)
0.2 (0.1–52.8)
197.0 (0.8–501)
86 (54–99)
82 (60–115)

48 (36–108)
6.8 (5–101)
12 (11–14)
354 (222–490)
7.0 (3.4–160)
69.6 (4.9–127)
84 (50–105)
63 (30–11)

0.48
0.10
0.36
0.61
0.004
,0.01
0.80
0.11

276 (144–708)
7.5 (5.5–9.5)
15.3 (13.4–16.6)
281 (211–463)
3.8 (0.1–201)
454 (124.8–501)
104 (52–138)
86 (76–114)

708 (204–984)
8.6 (5–11.3)
15.4 (13.4–16.9)
242 (201–312)
201 (3–201)
298 (76.3–501)
105.5 (95–131.5)
76.5 (56–98)

0.07
0.35
0.90
0.31
0.02
0.37
0.87
0.04

7 (5.2–10)
41.5 (35.9–49.4)
4 (2.1–6)
16.6 (11.4–20.5)
18.7 (15.7–21.8)
20.8 (9.1–29.6)

5 (5–7.4)
46.1 (29.1–49.8)
3.3 (2.9–3.9)
16.3 (14.9–20.9)
15.2 (13.5–17.1)
20.7 (15.5–22.6)

0.03
0.05
0.05
0.88
,0.001
0.52

11.8 (8.1–19.8)
41.4 (33–46.8)
4.3 (3.2–6)
12.6 (11.8–16.2)
18.2 (16.1–21.9)
22.8 (20.7–28)

19.6 (9.6–53)
42.7 (35.5–46.8)
4 (2.2–5.1)
15.5 (12–18.7)
16.2 (14.8–22.2)
20 (18–28.1)

0.30
0.36
0.23
0.006
0.05
0.04

Abbreviations: CMV, cytomegalovirus; Hb, hemoglobin; HSV, herpes simplex virus; IgG, immunoglobulin G; Mo, month; PLT, platelet; WBC, white blood cell count.
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Table 3 Coats’ disease comparison with controls: adjusted to
age and sex as confounding factors (logistic regression)
Variables

P-value

OR (95% CI)

Age
Sex
Serum anti-HSV IgG
Serum anti-CMV IgG
Serum beta globulin

0.82
0.16
0.01
0.07
0.02

0.99 (0.9–1.0)
0.12 (0.00–2.3)
0.94 (0.95–0.99)
1.01 (0.99–1.00)
1.80 (1.0–3.1)

Abbreviations: CI, confidence interval; HSV, herpes simplex virus; CMV,
cytomegalovirus; IgG, immunoglobulin G; OR, odds ratio.

plays a significant role in fat solubility.11 The globulin fraction of blood includes hundreds of serum proteins, including
carrier proteins, enzymes, complement, and immunoglobulins. Globulins are divided into four groups by electrophoresis: alpha, alpha-2, beta, and gamma, depending on their
migratory pattern between the anode and the cathode of the
electrophoresis test.11 The beta fraction of serum globulins
is known to have two peaks, named as beta 1 and beta 2.
Beta 1 is composed of mostly transferrin, and beta 2 contains
beta-lipoprotein.12 IgA, IgM, and sometimes IgG, along with
complement proteins (C3), beta-2 microglobulin, plasminogen, angiostatins, properdin, sex hormone-binding globulin,
transferrin, hemopexin, and factor H, can also be identified
in the beta fraction.10–12 These proteins carry out numerous
biological functions in the human body, including iron transport and monitoring immune response.10,11
Beta globulin protein can be elevated or depressed in
various diseases. Beta globulin is found to be elevated in
iron deficiency anemia, hypercholesterolemia, pregnancy,
estrogen therapy, and also substantially increased in liver
disease.9,10,13,14 It is found to be decreased in malnutrition, cirrhosis, and immune deficiency due to decreased synthesis, and
in nephrotic syndrome due to protein loss in the kidney.11
In this series of Coats’ disease, the beta globulin fraction
was elevated, which is particularly evident in patients lesser
than 10 years. This age-related difference could correlate with
milder manifestations of Coats’ disease in older patients. The
relationship of this fraction with Coats’ disease is unclear, but
could correlate to higher C3 (complement protein 3) level or
other factors. Complement 3 is an important protein in the
immune system, which plays a vital role in the acute phase
response. It controls several biological processes, including
cell lysis, chemotaxis, anaphylaxis, vascular permeability,
and cellular membrane adhesion. This protein is categorized
as a beta globulin and might represent the elevation of beta
globulin in Coats’ disease in this report.12,15–18
Chronic low-grade inflammation has been correlated
with elevated C-reactive protein, as well as complement
C3 plasma levels, and these can be predictive of arterial
Clinical Ophthalmology 2017:11

thrombotic events.16–20 Elevated C3 is also associated with
prolonged fibrinolysis.18,21–23 Both of these roles could relate
to the vascular pathology of Coats’ disease.
The discrepancy found in the younger and older age groups
could suggest a difference in the main pathophysiological
basis of Coats’ disease in children and adults. More studies
are needed for the confirmation of this observation. There are
limitations of this study, including the small sample size and
unclear relevance of beta-globulin relationship to the condition
studied. This relationship could be further explored with larger
cohort and more precise fractionation of the beta-globulin
subgroup to better understand the exact protein(s) that contribute to this finding and its relationship to Coats’ disease.

Conclusion
This analysis demonstrated that children with Coats’
disease showed elevated serum levels of beta globulin. We
speculate that this finding could reflect the known fluorescein
angiographic-evident ischemic component and possibly now
a low-grade inflammatory component.

Disclosure
The authors report no conflicts of interest in this work.
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